Update on herpes zoster vaccination: A family practitioner's guide;Mise à jour sur la vaccination contre l'herpès zoster: Guide à l'intention des médecins de famille

Canadian Family Physician

Volumn 57, Issue 10, 2011, Pages

  Shapiro, Marla ^a   Kvern, Brent ^b   Watson, Peter ^a   Guenther, Lyn ^c   McElhaney, Janet ^d   McGeer, Allison ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

^c UNIVERSITY OF WESTERN ONTARIO   (Canada)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ACICLOVIR; ANALGESIC AGENT; AZATHIOPRINE; CORTICOSTEROID; FAMCICLOVIR; MERCAPTOPURINE; METHOTREXATE; OPIATE; PLACEBO; PREDNISONE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; VALACICLOVIR; VARICELLA ZOSTER VACCINE;

CANADA; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CENTRAL NERVOUS SYSTEM INFECTION; CHICKENPOX; CLINICAL FEATURE; DERMATOME; DISEASE DURATION; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG SAFETY; GUILLAIN BARRE SYNDROME; HERPES ZOSTER; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPROMISED PATIENT; IMMUNOSUPPRESSIVE TREATMENT; INJECTION SITE ERYTHEMA; INJECTION SITE HEMATOMA; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE REACTION; INJECTION SITE SWELLING; LEUKEMIA; LYMPHOMA; NERVE PARALYSIS; NEUROMUSCULAR DISEASE; POSTHERPETIC NEURALGIA; PRACTICE GUIDELINE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; REYE SYNDROME; TREATMENT CONTRAINDICATION; VACCINATION; VARICELLA ZOSTER VIRUS; VIRAL EYE INFECTION; VIRUS REACTIVATION; VIRUS TRANSMISSION;

CANADA; DISEASE OUTBREAKS; FAMILY PRACTICE; HERPES ZOSTER; HERPES ZOSTER VACCINE; HERPESVIRUS 3, HUMAN; HUMANS; MIDDLE AGED; PHYSICIANS, FAMILY; UNITED STATES; VACCINATION;

EID: 80054704071     PISSN: 0008350X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (31)

1. Comité consultatif national de l'immunisation (CCNI). Statement on the recommended use of herpes zoster vaccine. Can Commun Dis Rep 2010;36(ACS-1):1-19. Accessible à: www.phac-aspc.gc.ca/publicat/ccdr- rmtc/10pdf/36-acs-1.pdf. Accédé le 16 aoÛt 2011.
2. Brisson M, Pellissier JM, Camden S, Quach C, De Wals P. The potential cost-effectiveness of vaccination against herpes zoster and post-herpetic neuralgia. Hum Vaccin 2008;4(3):238-45. Cyberpub. du 25 mai 2010.
3. Arvin A. Aging, immunity, and the varicella-zoster virus. N Engl J Med 2005;352(22):2266-7. (Pubitemid 40740549)
4. Hope-Simpson RE. Postherpetic neuralgia. J R Coll Gen Pract 1975;25(157):571-5.
5. De Moragas JM, Kierland RR. The outcome of patients with herpes zoster. AMA Arch Derm 1957;75(2):193-6.
6. Burgoon CF Jr, Burgoon JS, Baldridge GD. The natural history of herpes zoster. J Am Med Assoc 1957;164(3):265-9.
7. Watson CP, Evans RJ, Watt VR, Birkett N. Post-herpetic neuralgia: 208 cases. Pain 1988;35(3):289-97. (Pubitemid 19010485)
8. Li Q, Chen N, Yang J, Zhou M, Zhou D, Zhang Q, et collab. Antiviral treatment for preventing postherpetic neuralgia. Cochrane Database Syst Rev 2009;(2):CD006866.
9. Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, et collab. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005;352(22):2271-84.
10. Zostavax [monographie du produit]. Kirkland, QC: Merck Canada; 2011.
11. Harpaz R, Ortega-Sanchez IR, Seward JF; Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC). Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 257(RR-5):1-30
12. e Conférence annuelle de l'IDSA, 25 au 28 octobre 2008; Washington, DC.
13. Whitley RJ. 70-year-old woman with shingles: review of herpes zoster. JAMA 2009;302(1):73-80. Cyberpub. du 2 juin 2009.
14. Brisson M. Estimating the number needed to vaccinate to prevent herpes zoster-related disease, health care resource use and mortality. Can J Public Health 2008;99(5):383-6.
15. e Assemblée annuelle de l'Infectious Diseases Society of America; 21 au 24 octobre 2010; Vancouver, CB. Accessible à: http://idsa.confex.com/idsa/2010/ webprogram/Paper3363.html. Accédé le 16 aoÛt 2011.
16. Gnann JW Jr. Vaccination to prevent herpes zoster in older adults. J Pain 2008;9(1 Suppl 1):S31-6.
17. Donahue JG, Choo PW, Manson JE, Platt R. The incidence of herpes zoster. Arch Intern Med 1995;155(15):1605-9.
18. Kilgore PE, Kruszon-Moran D, Seward JF, Jumaan A, Van Loon FP, Forghani B, et collab. Varicella in Americans from NHANES III: implications for control through routine immunization. J Med Virol 2003;70(Suppl 1):S111-8.
19. Comité consultatif national de l'immunisation (CCNI). Update on varicella. Can Commun Dis Rep 2004;30:1-26. Accessible à: www.phac-aspc. gc.ca/publicat/ccdr-rmtc/04vol30/acs-dcc-1/index-eng.php. Accédé le 16 aoÛt 2011.
20. e éd. Ottawa, ON: Agence de la santé publique du Canada; 2006. Accessible à: http://origin.phac- aspc.gc.ca/publicat/cig-gci/ index-eng.php. Accédé le 16 aoÛt 2011.
21. Centers for Disease Control and Prevention [site web]. Herpes zoster vaccination of health care professionals. Atlanta, GA: Centers for Disease Control and Prevention; 2011. Accessible à: www.cdc.gov/vaccines/vpd-vac/ shingles/hcp-vaccination.htm. Accédé le 16 aoÛt 2011.
22. Tseng HF, Smith N, Sy LS, Jacobsen SJ. Evaluation of the incidence of herpes zoster after concomitant administration of zoster vaccine and polysaccharide pneumococcal vaccine. Vaccine 2011;29(20):3628-32. Cyberpub du 22 mars 2011.
23. Clinicaltrials.gov [site web]. ZOSTAVAX™ in patients on chronic/maintenance corticosteroids (V211-017). Bethesda, MD: National Institutes of Health; 2007. Trial no. NCT00546819. Accessible à: www.clinicaltrials. gov/ct2/show/NCT00546819?term=zoster+017&rank=2 2010. Accédé le 16 aoÛt 2011.
24. Kroger AT, Atkinson WL, Marcuse EK, Pickering LK; Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC). General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2006;55(RR-15):1-48.
25. e éd. Canberra, Aust: Department of Health and Ageing, Government of Australia; 2008. Accessible à: www. health.gov.au/internet/immunise/publishing.nsf/content/ handbookhome. Accédé le 16 aoÛt 2011.
26. Simberkoff MS, Arbeit RD, Johnson GR, Oxman MN, Boardman KD, Williams HM, et collab. Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial. Ann Intern Med 2010;152(9):545-54.
27. Schmid DS, Jumaan AO. Impact of varicella vaccine on varicella-zoster virus dynamics. Clin Microbiol Rev 2010;23(1):202-17.
28. Brisson M, Gay NJ, Edmunds WJ, Andrews NJ. Exposure to varicella boosts immunity to herpes-zoster: implications for mass vaccination against chickenpox. Vaccine 2002;20(19-20):2500-7. (Pubitemid 34615588)
29. Tseng HF, Smith N, Harpaz R, Bialek SR, Sy LS, Jacobsen SJ. Herpes zoster vaccine in older adults and the risk of subsequent herpes zoster disease. JAMA 2011;305(2):160-6.
30. Najafzadeh M, Marra CA, Galanis E, Patrick DM. Cost effectiveness of herpes zoster vaccine in Canada. Pharmacoeconomics 2009;27(12):991-1004. DOI: 10.2165/11314010-000000000-00000.
31. Johnson R, McElhaney J, Pedalino B, Levin M. Prevention of herpes zoster and its painful and debilitating complications. Int J Infect Dis 2007;11(Suppl 2):S43-8. (Pubitemid 350302067)